

NISCH Antibody (N-Term)

Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP22144a

Specification

NISCH Antibody (N-Term) - Product Information

Application WB,E
Primary Accession Q9Y2I1

Reactivity Human, Mouse

Host Rabbit
Clonality polyclonal
Isotype Rabbit IgG
Calculated MW 166629

NISCH Antibody (N-Term) - Additional Information

Gene ID 11188

Other Names

Nischarin, Imidazoline receptor 1, I-1, IR1, Imidazoline receptor antisera-selected protein, hIRAS, Imidazoline-1 receptor, I1R, Imidazoline-1 receptor candidate protein, I-1 receptor candidate protein, I1R candidate protein, NISCH, IRAS, KIAA0975

Target/Specificity

This NISCH antibody is generated from a rabbit immunized with a KLH conjugated synthetic peptide between 5-38 amino acids from human NISCH.

Dilution

WB~~1:2000

Format

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.

Storage

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions

NISCH Antibody (N-Term) is for research use only and not for use in diagnostic or therapeutic procedures.

NISCH Antibody (N-Term) - Protein Information

Name NISCH

Synonyms IRAS, KIAA0975



Function Acts either as the functional imidazoline-1 receptor (I1R) candidate or as a membrane-associated mediator of the I1R signaling. Binds numerous imidazoline ligands that induces initiation of cell-signaling cascades triggering to cell survival, growth and migration. Its activation by the agonist rilmenidine induces an increase in phosphorylation of mitogen-activated protein kinases MAPK1 and MAPK3 in rostral ventrolateral medulla (RVLM) neurons that exhibited rilmenidine-evoked hypotension (By similarity). Blocking its activation with efaroxan abolished rilmenidine-induced mitogen-activated protein kinase phosphorylation in RVLM neurons (By similarity). Acts as a modulator of Rac-regulated signal transduction pathways (By similarity). Suppresses Rac1-stimulated cell migration by interacting with PAK1 and inhibiting its kinase activity (By similarity). Also blocks Pak-independent Rac signaling by interacting with RAC1 and inhibiting Rac1-stimulated NF-kB response element and cyclin D1 promoter activation (By similarity). Inhibits also LIMK1 kinase activity by reducing LIMK1 'Tyr-508' phosphorylation (By similarity). Inhibits Rac-induced cell migration and invasion in breast and colon epithelial cells (By similarity). Inhibits lamellipodia formation, when overexpressed (By similarity). Plays a role in protection against apoptosis. Involved in association with IRS4 in the enhancement of insulin activation of MAPK1 and MAPK3. When overexpressed, induces a redistribution of cell surface ITGA5 integrin to intracellular endosomal structures.

Cellular Location

Cell membrane. Cytoplasm. Early endosome. Recycling endosome. Note=Enriched in the early/sorting and recycling endosomes. Colocalized in early/sorting endosomes with EEA1 and SNX2 and in recycling endosomes with transferrin receptor. Detected in the perinuclear region partially associated with punctate structures (By similarity). Colocalizes with PAK1 in cytoplasm, vesicular structures in the perinuclear area and membrane ruffles (By similarity) Colocalizes with RAC1 in the cytoplasm and vesicles structures (By similarity). Colocalized with MAPK1 and MAPK3 in RVLM neurons (By similarity).

Tissue Location

Isoform 1, isoform 3 and isoform 4 are expressed in brain. Isoform 1 is expressed in endocrine tissues


NISCH Antibody (N-Term) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- <u>Immunohistochemistry</u>
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

NISCH Antibody (N-Term) - Images





All lanes : Anti-NISCH Antibody (N-Term) at 1:2000 dilution Lane 1: Hela whole cell lysate Lane 2: mouse brain lysate Lysates/proteins at 20 μ g per lane. Secondary Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 167 kDa Blocking/Dilution buffer: 5% NFDM/TBST.

NISCH Antibody (N-Term) - Background

Acts either as the functional imidazoline-1 receptor (I1R) candidate or as a membrane-associated mediator of the I1R signaling. Binds numerous imidazoline ligands that induces initiation of cell-signaling cascades triggering to cell survival, growth and migration. Its activation by the agonist rilmenidine induces an increase in phosphorylation of mitogen-activated protein kinases MAPK1 and MAPK3 in rostral ventrolateral medulla (RVLM) neurons that exhibited rilmenidine-evoked hypotension (By similarity). Blocking its activation with efaroxan abolished rilmenidine-induced mitogen-activated protein kinase phosphorylation in RVLM neurons (By similarity). Acts as a modulator of Rac-regulated signal transduction pathways (By similarity). Suppresses Rac1-stimulated cell migration by interacting with PAK1 and inhibiting its kinase activity (By similarity). Also blocks Pak-independent Rac signaling by interacting with RAC1 and inhibiting Rac1-stimulated NF-kB response element and cyclin D1 promoter activation (By similarity). Inhibits also LIMK1 kinase activity by reducing LIMK1 'Tyr-508' phosphorylation (By similarity). Inhibits Rac-induced cell migration and invasion in breast and colon epithelial cells (By similarity). Inhibits lamellipodia formation, when overexpressed (By similarity). Plays a role in protection against apoptosis. Involved in association with IRS4 in the enhancement of insulin activation of MAPK1 and MAPK3. When overexpressed, induces a redistribution of cell surface ITGA5 integrin to intracellular endosomal structures.

NISCH Antibody (N-Term) - References

Piletz J.E., et al.DNA Cell Biol. 19:319-329(2000). Piletz J.E., et al.Ann. N. Y. Acad. Sci. 1009:419-426(2003). Nagase T., et al.DNA Res. 6:63-70(1999). Ota T., et al.Nat. Genet. 36:40-45(2004). Bechtel S., et al.BMC Genomics 8:399-399(2007).